EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Clinical data comparison for FDA-approved gene therapies in sickle cell disease

Alexis Leonard, Julie Kanter

Experimental Biology and Medicine · 2025

DOI: 10.3389/ebm.2025.10806 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Experimental Biology and Medicine, 2025. Verfasst von Alexis Leonard und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, United States. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Genetic Therapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sickle cell disease (SCD) is a severe inherited hemoglobinopathy with limited curative treatment options. In December 2023, the U.S. FDA approved two autologous gene therapies, lovo-cel (bluebird bio) and exa-cel (Vertex/CRISPR Therapeutics), offering potentially transformative outcomes. We performed a comparative analysis of these therapies based on published clinical trial design, patient eligibility, manufacturing requirements, and reported efficacy and safety outcomes. Overall, participants treated with lovo-cel had more severe baseline disease, reflected by a higher median rate of vaso-occlusive events (VOEs), despite the use of a more stringent VOE definition. Mobilization of hematopoietic stem cells (HSCs) with single-agent plerixafor proved challenging in both trials, with most participants requiring multiple mobilization and apheresis cycles. A greater proportion of exa-cel participants required three or more apheresis procedures, driven by higher CD34 + cell dose targets needed to compensate for CRISPR-associated HSC loss. Both therapies demonstrated greater than 90% resolution of severe VOEs, with near-complete resolution in pediatric participants. A small subset of participants experienced VOEs post-treatment, including events occurring beyond the primary efficacy assessment period. Notably, no recurrent strokes were reported among lovo-cel treated participants with a history of overt stroke. Both therapies provide durable, clinically meaningful benefit and represent a major advancement in SCD management. However, differences in trial populations, cell collection logistics, and manufacturing have important implications for real-world applications. Continued long-term follow-up and the establishment of standardized post-treatment registries will be critical to fully assess durability, monitor late effects, and inform patient selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellGenetic TherapyHumansUnited StatesUnited States Food and Drug AdministrationMaleFemaleTreatment OutcomeChildHematopoietic Stem Cell TransplantationAdultHematopoietic Stem Cell MobilizationAdolescentClinical Trials as Topic

Stichwörter der Autor:innen

autologous transplantationexal-celgene therapylovo-celsickle cell disease

Autor:innen und Institutionen

  • Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, United States.
  • Division of Hematology, University of Alabama at Birmingham, Birmingham, AL, United States.

Zitieren

APA

Leonard, A., & Kanter, J. (2025). Clinical data comparison for FDA-approved gene therapies in sickle cell disease. Experimental Biology and Medicine. https://doi.org/10.3389/ebm.2025.10806

Vancouver

Leonard A, Kanter J. Clinical data comparison for FDA-approved gene therapies in sickle cell disease. Experimental Biology and Medicine. 2025. doi:10.3389/ebm.2025.10806

BibTeX
@article{Leonard2025,
  author = {Leonard, Alexis and Kanter, Julie},
  title = {Clinical data comparison for FDA-approved gene therapies in sickle cell disease},
  journal = {Experimental Biology and Medicine},
  year = {2025},
  doi = {10.3389/ebm.2025.10806}
}
Kostenlos starten →